Tectonic Therapeutic (NASDAQ:TECX) & X4 Pharmaceuticals (NASDAQ:XFOR) Head-To-Head Survey

Tectonic Therapeutic (NASDAQ:TECX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Institutional & Insider Ownership

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Tectonic Therapeutic and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-41.05%	-37.33%
X4 Pharmaceuticals	N/A	-163.17%	-54.32%

Volatility and Risk

Tectonic Therapeutic has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

Valuation & Earnings

This table compares Tectonic Therapeutic and X4 Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	$12.16 million	($5.17)	-7.91
X4 Pharmaceuticals	N/A	N/A	-$101.17 million	$0.08	6.49

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Tectonic Therapeutic and X4 Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0	0	4	1	3.20
X4 Pharmaceuticals	0	1	2	0	2.67

Tectonic Therapeutic currently has a consensus target price of $60.00, indicating a potential upside of 46.77%. X4 Pharmaceuticals has a consensus target price of $3.67, indicating a potential upside of 606.49%. Given X4 Pharmaceuticals’ higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Tectonic Therapeutic.

Summary

Tectonic Therapeutic beats X4 Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.